Global Short Bowel Syndrome Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug;

Glucagon-like Peptide-2 (GLP-2) Analog - Short-acting GLP-2 Analog[Teduglutide (Gattex/Revestive)], - Long-acting GLP-2 Analog[Glepaglutide, Apraglutide (FE 203799) and Others], Glutamine, Growth Hormone, Glucagon-like Peptide-1 (GLP-1) Analog, Insulin (NTRA 9620), TGR5 Agonist and Others.

By Route of Administration;

Injectable and Oral.

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn148937477 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Short Bowel Syndrome Therapeutics Market (USD Million), 2021 - 2031

In the year 2024, the Global Short Bowel Syndrome Therapeutics Market was valued at USD 1,624.02 million. The size of this market is expected to increase to USD 6,893.56 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 22.9%.

Short bowel syndrome (SBS) presents a complex challenge in the realm of gastrointestinal disorders, characterized by the insufficient functional intestine to maintain proper nutrient absorption. This condition typically arises due to extensive surgical resection, often necessitated by conditions like Crohn's disease, mesenteric ischemia, or other gastrointestinal complications. Despite being a rare condition, its impact on patients can be profound, leading to malabsorption, dehydration, malnutrition, and other severe health complications. Consequently, the therapeutic landscape for SBS has garnered increasing attention from pharmaceutical companies and researchers aiming to address the unmet medical needs of affected individuals.

The global short bowel syndrome therapeutics market is witnessing a surge in research and development efforts aimed at novel treatment modalities to improve patient outcomes. Historically, the management of SBS has relied on supportive measures such as dietary modifications, parenteral nutrition, and in some cases, surgical interventions like intestinal transplantation. However, these approaches often come with significant limitations, including complications, cost, and reduced quality of life. As a result, there is a growing demand for more targeted and effective pharmacological interventions that can enhance intestinal adaptation, promote nutrient absorption, and mitigate the debilitating symptoms associated with SBS.

In recent years, advancements in biotechnology and pharmaceutical innovation have spurred the development of promising therapeutics tailored specifically for SBS. These include novel drugs targeting various pathways involved in intestinal function and nutrient absorption, such as growth factors, hormone analogs, bile acid modulators, and intestinal permeability enhancers. Additionally, ongoing clinical trials are exploring the potential of gene therapy, stem cell transplantation, and tissue engineering approaches to address the underlying pathophysiology of SBS and restore intestinal function. With a deepening understanding of the molecular mechanisms driving SBS, researchers are increasingly optimistic about the prospect of more targeted and personalized treatment strategies that could revolutionize the management of this challenging condition.

The global short bowel syndrome therapeutics market is poised for significant growth in the coming years, driven by a combination of technological advancements, expanding research initiatives, and increasing investment in rare disease drug development. However, key challenges remain, including the need for robust clinical evidence, regulatory hurdles, and accessibility issues. Nevertheless, with continued innovation and collaboration across the healthcare ecosystem, there is considerable optimism about the potential to improve the lives of individuals living with SBS and pave the way for more effective and sustainable treatment options in the future.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug
    2. Market Snapshot, By Route of Administration
    3. Market Snapshot, By Distribution Channel
    4. Market Snapshot, By Region
  4. Global Short Bowel Syndrome Therapeutics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Technological advancements
        2. Increasing healthcare expenditure
        3. Rising prevalence of short bowel syndrome
        4. Growing demand for effective treatments
      2. Restraints
        1. Limited awareness
        2. High treatment costs
        3. Stringent regulatory requirements
        4. Side effects of existing therapies
      3. Opportunities
        1. Novel drug development
        2. Emerging markets expansion
        3. Collaborative research initiatives
        4. Personalized medicine approaches
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Short Bowel Syndrome Therapeutics Market, By Drug, 2021 - 2031 (USD Million)
      1. Glucagon-like Peptide-2 (GLP-2) Analog
        1. Short-acting GLP-2 Analog
          1. Teduglutide (Gattex/Revestive)
        2. Long-acting GLP-2 Analog
          1. Glepaglutide
          2. Apraglutide (FE 203799)
          3. Others
      2. Glutamine
      3. Growth Hormone
      4. Glucagon-like Peptide-1 (GLP-1) Analog
      5. Insulin (NTRA 9620)
      6. TGR5 Agonist
      7. Others
    2. Global Short Bowel Syndrome Therapeutics Market, By Route of Administration, 2021 - 2031 (USD Million)
      1. Injectable
      2. Oral
    3. Global Short Bowel Syndrome Therapeutics Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    4. Global Short Bowel Syndrome Therapeutics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Takeda Pharmaceutical Company Limited
      2. AbbVie Inc
      3. Novartis International AG
      4. Pfizer Inc
      5. Shire
      6. Fresenius Kabi AG
      7. Nestlé Health Science
      8. Emmaus Life Sciences, Inc
      9. Zealand Pharma A/S
      10. Nutrinia Ltd
  7. Analyst Views
  8. Future Outlook of the Market